Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.
Sebastian Eduardo SattuiJean W LiewKevin KennedyEmily SirotichMichael PutmanTarin T MoniAkpabio AkpabioDeshiré Alpizar-RodriguezFrancis BerenbaumInita BulinaRichard P ConwayAman Dev SinghEimear DuffKaren L DurrantTamer A GheitaCatherine L HillRichard A HowardBimba F HoyerEvelyn HsiehLina El KibbiAdam KilianAlfred Hyoungju KimDavid F L LiewChieh LoBruce MillerSerena MingollaMichal NudelCandace A PalmerleeJasvinder A SinghNamrata SinghManuel Francisco Ugarte-GilJohn WallaceKristen J YoungSuleman BhanaWendy CostelloRebecca GraingerPedro M MachadoPhilip C RobinsonPaul SufkaZachary S WallaceJinoos YazdanyCarly HarrisonMaggie LarchéMitchell LevineGary FosterLehana ThabaneLisa G RiderJonathan S HausmannJulia F SimardJeffrey A SparksPublished in: RMD open (2021)
Among adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.